Sequenom Inc. - SQNM- Profile

Sequenom Incorporated. The Group's principal activity is to determine the medical impact of genes and genetic variations known as single nucleotide polymorphisms. The Group operates in two business segments. SEQUENOM Genetic Systems is dedicated to the sales and support of our MassARRAY products and the continued expansion of platform applications. SEQUENOM Pharmaceuticals applies the power of human genetics to systematically identify disease-related genes that affect significant portions of the overall population. The pharmaceutical unit focuses on disease gene discovery, target identification, functional validation and ultimately diagnostic and therapeutic product development. SEQUENOM, MassARRAY, RealSNP and SpectroCHIP are the trademarks of the Group. The Group has operations in the United States, Germany and the United Kingdom. On 03-Sep-2002, the Group acquired Axiom Biotechnologies. Sequenom Genetic systems accounted for 98% of 2002 revenues and Sequenom Pharmaceuticals, 2%.